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Abstract
Progeroid laminopathies are accelerated aging syndromes caused by defects in nuclear envelope proteins.
Accordingly, mutations in the LMNA gene and functionally related genes have been described to cause HGPS
(Hutchinson–Gilford progeria syndrome), MAD (mandibuloacral dysplasia) or RD (restrictive dermopathy).
Functional studies with animal and cellular models of these syndromes have facilitated the identiﬁcation
of the molecular alterations and regulatory pathways involved in progeria development. We have recently
described a novel regulatory pathway involving miR-29 and p53 tumour suppressor which has provided
valuable information on the molecular components orchestrating the response to nuclear damage stress.
Furthermore, by using progeroid mice deﬁcient in ZMPSTE24 (zinc metalloprotease STE24 homologue)
involved in lamin A maturation, we have demonstrated that, besides these abnormal cellular responses
to stress, dysregulation of the somatotropic axis is responsible for some of the alterations associated with
progeria. Consistent with these observations, pharmacological restoration of the somatotroph axis in these
mice delays the onset of their progeroid features, signiﬁcantly extending their lifespan and supporting
the importance of systemic alterations in progeria progression. Finally, we have very recently identiﬁed a
novel progeroid syndrome with distinctive features from HGPS and MAD, which we have designated NGPS
(Ne´stor–Guillermo progeria syndrome) (OMIM #614008). This disorder is caused by a mutation in BANF1, a
gene encoding a protein with essential functions in the assembly of the nuclear envelope, further illustrating
the importance of the nuclear lamina integrity for human health and providing additional support to the
study of progeroid syndromes as a valuable source of information on human aging.
Introduction
The nuclear envelope is a complex structure that surrounds
and protects the genome, playing essential roles in its
regulation, organization and maintenance [1]. The nuclear
envelope is composed of twomembrane bilayers with nuclear
pores that control traffic in and out the nucleus [2,3].
The nuclear face of the inner membrane is covered by
the nuclear lamina, a protein network that provides scaffold
for nuclear envelope proteins and chromatin [4]. In humans,
three genes named LMNA, LMNB1 and LMNB2 encode
nuclear lamins. Whereas the two B-type lamins are encoded
by two independent genes, LMNB1 and LMNB2, the
LMNA gene encodes lamin A and lamin C proteins by
alternative splicing. Mutations in A-type lamins, lamin B and
several lamin-binding proteins (emerin, MAN1 and lamin
B receptor) have been found mutated in different human
diseases which are collectively known as laminopathies [5].
The range, diversity and tissue-specificity of laminopathy
phenotypes are providing valuable clues about the cellular
functions of lamins and lamin-related proteins.
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Progeroid laminopathies are human syndromes of ac-
celerated aging caused by defects in the nuclear lamina
[6,7]. Among them, HGPS (Hutchinson–Gilford progeria
syndrome) is the best known. Affected patients show growth
impairment, lipodystrophy, dermal and bone abnormalities
and cardiovascular alterations, leading to a shortened
lifespan [8–10]. HGPS is caused in most cases by a de
novo point mutation within exon 11 of the LMNA gene
encoding lamin A (c.1824C>T; p.G608G) [11,12]. Lamin
A undergoes a complex maturation process, including the
addition of a farnesyl group and a proteolytic processing
event carried out by the metalloprotease ZMPSTE24 (zinc
metalloprotease STE24 homologue)/FACE1 (farnesylated
proteins-converting enzyme 1) [13]. The G608G mutation
activates a cryptic splicing donor site, leading to the
accumulation of a truncated form of prelamin A, called
LA50 or progerin, which lacks a 50-residue-long fragment
containing the target sequence for the final proteolytic
step carried out by ZMPSTE24/FACE1. Consequently, this
aberrant lamin A isoform remains constitutively farnesylated
[14,15].
The use of cellular and murine models of progeroid
laminopathies [14–19] has provided valuable information
about the molecular alterations involved in progeria, such
as the involvement of the p53 tumour suppressor [20], the
altered biology of adult stem cells [21] or the presence of
metabolic alterations [22,23]. These studies have allowed the
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development of the first therapeutic approaches for patients
with HGPS [24–28]. Currently, two clinical trials are being
carried out based on a combination of statins and amino
bisphosphonates, alone or complemented with a low dose
of a farnesyltransferase inhibitor (http://clinicaltrials.gov;
NCT00731016 and NCT00916747).
Although murine models of progeroid laminopathies have
been essential for understanding the pathways and alterations
that drive progeria development, important questions remain
to be answered, especially those related to the regulatory
mechanisms that control and integrate the altered pathways,
the specific contribution of cellular and systemic alterations
to the progeroid phenotype, as well as the specific function of
each nuclear lamina component. In this regard, three recent
reports from our laboratory have shed light on these points,
highlighting the importance of nuclear envelope for human
health [28–30].
An miR-29/p53 regulatory circuit involved
in aging and chronic DNA damage response
A common feature of aging is the progressive accumulation
of cellular damage. Several stressors have been proposed
to contribute to this situation, such as oxidative reactions,
telomere attrition or the decline of DNA repair and protein
turnover systems [31,32]. Progeroid syndromes associated
with lamin A alterations show genomic instability as a
consequence of the nuclear envelope disruption [33]. This
stress triggers a series of cellular and systemic events
directed to the restoration of cellular and organismal
homoeostasis, which are ultimately responsible for many
of the alterations characteristic of these syndromes. In this
regard, important changes in chromatin organization and
transcriptional profiles have been described inmurinemodels
of HGPS [20,34], but little is known about the molecular
components that orchestrate these changes.
Over the last decade, miRNAs (microRNAs) have
emerged as a new and fundamental level of gene regulation.
Each miRNA has the potential ability to repress the
translation of hundreds of transcripts and their impact on
a great number of cellular processes has been broadly proved.
To explore the possible involvement of miRNAs in progeria
development, we have performed a miRNA transcriptome
analysis in the liver of Zmpste24-deficient mice [29]. Among
thedifferentially expressedmiRNAs, three of them (miR-29a,
miR-29b and miR-29c), belonging to the miR-29 family, are
significantly up-regulated in tissues of Zmpste24 progeroid-
knockout mice.
Through a series of functional analysis, we have found
that miR-29 plays a pivotal role in the regulation of
cell survival and proliferation through the modulation
of the DNA damage response in a p53-dependent way.
Thus the p53-mediated activation of the DNA damage
response in Zmpste24-deficient cells [35] would trigger
multiple effector pathways, including an increase in miR-
29 expression (Figure 1). Among the potential targets of
Figure 1. Cellular and systemic alterations involved in progeroid
laminopathies
The accumulation of farnesylated forms of prelamin A at the nuclear
envelope causes severe alterations in nuclear dynamics, triggering
an adaptive response aimed at preserving organism viability under
compromising circumstances. At a cellular level, the p53 signalling
pathway orchestrates a chronic DNA damage response that involves
miR-29 transcriptional activation. Thus miR-29-mediated repression of
Ppm1d phosphatase reinforces this stress response, favouring a decrease
in cellular proliferation rates accompanied by an increase in apoptosis
and senescence. These processes result in the loss of tissue and organism
homoeostasis. In parallel, a chronic stress response cause changes in
the transcriptional proﬁles of several somatotroph axis key regulators,
such as Igfbp1 (IGF-binding protein 1), Socs2 (suppressor of cytokine
signalling 2), miR-1 or Igfals (IGF-binding protein, acid-labile subunit).
These alterations dramatically reduce the levels of circulating IGF-1,
which, together with the increased production of GH at the
pituitary gland, favours a systemic metabolic switch towards somatic
maintenance at the expense of somatic growth.
miR-29, Ppm1d/Wip1 phosphatase has been proposed as
the key mediator for this effect. Ppm1d is a phosphatase
that acts as a negative regulator of DNA damage response
by dephosphorylating important components of this process
such as p53, Chk1 (checkpoint kinase 1), Chk2 (checkpoint
kinase 2), p38, γ -H2AX (phosphorylated histone H2AX) or
ATM (ataxia telangiectasia mutated) [36,37]. Thus a decrease
in Ppm1d levels mediated by miR-29 would contribute to
the activation of the DNA damage response. In agreement
with these results, miR-29 has been described as a tumour-
suppressor miRNA in several human cancers. This
tumour-suppressive function could be consistent with a pro-
aging role for this miRNA, since a growing number of
tumour-suppressor genes have been reported to be aging
promoters, which could be illustrative examples of the
antagonistic pleiotropy phenomenon [38].
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Somatotroph suppression in
Zmpste24-deﬁcient mice
Although the dynamics of aging are far frombeing completely
understood, our knowledge of the systemic factors involved
in this process has considerably increased in recent years [39–
41]. Somatotroph signalling has been identified as a major
regulator of longevity from nematodes to humans [42]. Para-
doxically, studies in different organisms have shown that the
reduction of this signalling is a common feature of both long-
lived model organisms and different progeroid mice [43,44].
In this sense, Zmpste24-deficient mice show a profound
dysregulation of GH (growth hormone)/IGF-1 (insulin-like
growth factor 1) balance, with a progressive reduction of
blood IGF-1 levels, accompanied by a progressive increase
in GH levels and a marked transcriptional alterations in
key genes for somatotroph signalling [28] (Figure 1). Thus
somatotroph alterations would be responsible for important
features of progeroid phenotype such as reduced growth
rate and body size. In this case, the observed alterations
in somatotropic axis seem to constitute a detrimental
phenomenon, rather than a successful adaptive strategy, as
demonstrated by the fact that the treatment of Zmpste24-
deficient mice with rIGF-1 (recombinant IGF-1) is able
to ameliorate some of the progeroid features of these
mice. rIGF-1-treated mice showed improved body weight,
increased amounts of subcutaneous fat deposits, reduced
degree of lordokyphosis and alopecia, and significantly
extended longevity. Accordingly, rIGF-1 treatment could be
a therapeutic approach to slow down disease progression in
children with progeria [45].
Interestingly,many pathological features ofGH resistance,
also known as Laron syndrome, are characteristic of
progeroid mice. Both Zmpste24− /− mice and patients with
this syndrome show reduced muscle development, strength
and endurance, as well as decreased bone mineral density,
alopecia, skin atrophy and hypoglycaemia [14,22,46]. Some
of these alterations could be consequence of an adaptive
stress response aimed at preserving organism viability under
compromising circumstances by reallocating resources from
growth to somatic preservation. In Zmpste24-knockout
mice, this systemic response could represent an attempt to
reduce replication defects, chromosomal instability, nuclear
envelope abnormalities and, finally, the risk of developing
cancer by decreasing metabolic activity. This hypothesis is
supported by the fact that patients with Laron syndrome or
other somatotroph-related pathologies such as GH receptor
deficiency exhibit a notable reduction in the incidence of
malignancies [47,48].
NGPS, a new hereditary progeroid
syndrome caused by BANF1 mutation
The recent availability of high-throughput sequencing tech-
nologies hasmade it possible to address personal genomepro-
jects that could uncover the precise causes of human genetic
diseases [49,50]. Thus exome sequencing of two unrelated
patients that exhibit a progeroid syndromewithoutmutations
in LMNA or ZMPSTE24 has allowed the identification of
a homozygous mutation in BANF1 (c.34G>C; p.A12T),
encoding BAF (barrier to autointegration factor 1), as the
molecular abnormality responsible for this syndrome [30].
Affected patients of this disease, called NGPS (Ne´stor–
Guillermo progeria syndrome) (OMIM #614008), partially
phenocopy HGPS and MAD (mandibuloacral dysplasia),
but also exhibit distinctive features, including the absence
of cardiovascular alterations and metabolic anomalies, a very
severe osteolysis and a relatively long lifespan of affected
individuals [51]. NGPS can be considered as a chronic
progeria because of its early onset but slow clinical course,
which leads to a relatively long survival of patients.
BAF is a small protein (89 amino acids) highly
conserved among metazoans [52,53]. BAF binds directly to
double-stranded DNA, chromatin, nuclear lamina proteins
(including lamin A and emerin), histones and transcription
factors, these being required for higher-order organization of
chromatin, nuclear envelope assembly, retrovirus infectivity
and transcription of specific genes [54].
The A12T mutation in NGPS patients affects a highly
conserved residue located at the surface of the protein,
decreasing its stability. Skin fibroblasts from these patients
show very low protein levels of BAF compared with control
fibroblasts and exhibit profound nuclear abnormalities,
including blebs and other aberrations associated with
progeroid laminopathies. In fact, BAF reduction is correlated
with mislocalization of emerin, which shows a predominant
cytoplasmic localization in mutant cells. Taken together,
these findings demonstrate the relevance of BAF in nuclear
envelope dynamics, providing new insights about the
relationship of nuclear envelope to aging.
Conclusions and perspectives
Over the last few years, the generation of experimental
murine models of progeroid laminopathies has been crucial
for a deeper understanding of the molecular basis of these
diseases. This is the case for HGPS, where a fast progress
has been made in the last 8 years since the identification of
LMNA mutations to the first clinical trial in HGPS patients.
However, new murine models that fully recapitulate all the
disease phenotypes of HGPS [55] are necessary to boost the
development of in vivo approaches directed to the correction
of LMNA aberrant splicing [25]. Besides, several questions
remain to be answered concerning important aspects such
as the relative contribution to the progeroid phenotype of
cell-autonomous compared with systemic alterations or the
involvement of nuclear envelope dynamics during normal
aging [56–58].
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